The Experts below are selected from a list of 86793 Experts worldwide ranked by ideXlab platform

Shabir A Madhi - One of the best experts on this subject based on the ideXlab platform.

Marvin Pomerantz - One of the best experts on this subject based on the ideXlab platform.

  • Pulmonary resection for multi–drug resistant Tuberculosis
    The Journal of thoracic and cardiovascular surgery, 2001
    Co-Authors: Pomerantz Benjamin, Joseph C. Cleveland, Heather K. Olson, Marvin Pomerantz
    Abstract:

    Abstract Objectives: Mycobacterium Tuberculosis continues to be a major cause of morbidity and mortality throughout the world. Complacency by the medical profession and by patients has caused a new strain of Mycobacterium Tuberculosis to emerge that is highly resistant to current antibiotics. The possibility of a new worldwide epidemic of drug-resistant Mycobacterium Tuberculosis is of concern. Optimal therapy for patients infected with multi–drug resistant Tuberculosis often requires surgical intervention to eradicate the infection. We report on our experience with pulmonary resection for multi–drug resistant Tuberculosis. Methods: During a 17-year period, 172 patients underwent 180 pulmonary resections. All patients had multi–drug resistant Tuberculosis and had a minimum of 3 months of medical therapy before surgery. Muscle flaps were frequently used to avoid residual space and bronchial stump problems. Results: During the study period, 98 lobectomies and 82 pneumonectomies were performed. Eight patients underwent multiple procedures. Operative mortality was 3.3% (6/180). Three patients died of respiratory failure, 2 patients died of a cerebrovascular accident, and 1 patient had a myocardial infarction. Late mortality was 6.8% (11/166). Significant morbidity was 12% (20/166). One half (91) of the patients had positive sputum at the time of surgery. After the operation, the sputum remained positive in only 4 (2%) patients. Mean length of follow-up was 7.6 years (range 4-204 months). Conclusions: Surgery remains an important adjunct to medical therapy for the treatment of multi–drug resistant Mycobacterium Tuberculosis. In the setting of localized disease, persistent sputum positivity, or patient intolerance of medical therapy, pulmonary resection should be undertaken. Pulmonary resection for multi–drug resistant Tuberculosis can be performed with acceptable operative morbidity and mortality. (J Thorac Cardiovasc Surg 2001;121:448-53)

Ebrahim Variava - One of the best experts on this subject based on the ideXlab platform.

Lee Fairlie - One of the best experts on this subject based on the ideXlab platform.

Pomerantz Benjamin - One of the best experts on this subject based on the ideXlab platform.

  • Pulmonary resection for multi–drug resistant Tuberculosis
    The Journal of thoracic and cardiovascular surgery, 2001
    Co-Authors: Pomerantz Benjamin, Joseph C. Cleveland, Heather K. Olson, Marvin Pomerantz
    Abstract:

    Abstract Objectives: Mycobacterium Tuberculosis continues to be a major cause of morbidity and mortality throughout the world. Complacency by the medical profession and by patients has caused a new strain of Mycobacterium Tuberculosis to emerge that is highly resistant to current antibiotics. The possibility of a new worldwide epidemic of drug-resistant Mycobacterium Tuberculosis is of concern. Optimal therapy for patients infected with multi–drug resistant Tuberculosis often requires surgical intervention to eradicate the infection. We report on our experience with pulmonary resection for multi–drug resistant Tuberculosis. Methods: During a 17-year period, 172 patients underwent 180 pulmonary resections. All patients had multi–drug resistant Tuberculosis and had a minimum of 3 months of medical therapy before surgery. Muscle flaps were frequently used to avoid residual space and bronchial stump problems. Results: During the study period, 98 lobectomies and 82 pneumonectomies were performed. Eight patients underwent multiple procedures. Operative mortality was 3.3% (6/180). Three patients died of respiratory failure, 2 patients died of a cerebrovascular accident, and 1 patient had a myocardial infarction. Late mortality was 6.8% (11/166). Significant morbidity was 12% (20/166). One half (91) of the patients had positive sputum at the time of surgery. After the operation, the sputum remained positive in only 4 (2%) patients. Mean length of follow-up was 7.6 years (range 4-204 months). Conclusions: Surgery remains an important adjunct to medical therapy for the treatment of multi–drug resistant Mycobacterium Tuberculosis. In the setting of localized disease, persistent sputum positivity, or patient intolerance of medical therapy, pulmonary resection should be undertaken. Pulmonary resection for multi–drug resistant Tuberculosis can be performed with acceptable operative morbidity and mortality. (J Thorac Cardiovasc Surg 2001;121:448-53)